William Blair Issues Pessimistic Estimate for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities research analysts at William Blair cut their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a note issued to investors on Wednesday, May 7th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of ($0.52) per share for the quarter, down from their prior forecast of ($0.21). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($0.60) EPS.

A number of other research analysts also recently commented on APLS. Robert W. Baird cut their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research report on Thursday, May 8th. The Goldman Sachs Group cut their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Needham & Company LLC dropped their price objective on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Scotiabank decreased their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating for the company in a report on Thursday, May 8th. Finally, Royal Bank of Canada cut their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a report on Thursday, May 8th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $41.37.

Apellis Pharmaceuticals Stock Down 1.4%

Apellis Pharmaceuticals stock opened at $17.28 on Monday. The stock has a market cap of $2.17 billion, a PE ratio of -8.51 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock’s fifty day moving average is $20.99 and its two-hundred day moving average is $26.99. Apellis Pharmaceuticals has a 1-year low of $16.65 and a 1-year high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same period last year, the firm posted ($0.54) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Algert Global LLC boosted its stake in shares of Apellis Pharmaceuticals by 20.0% during the first quarter. Algert Global LLC now owns 338,613 shares of the company’s stock valued at $7,405,000 after acquiring an additional 56,328 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Apellis Pharmaceuticals in the first quarter valued at $344,000. Russell Investments Group Ltd. increased its stake in shares of Apellis Pharmaceuticals by 537.0% during the 1st quarter. Russell Investments Group Ltd. now owns 38,903 shares of the company’s stock valued at $851,000 after acquiring an additional 32,796 shares during the last quarter. Nuveen LLC purchased a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth about $10,765,000. Finally, Aigen Investment Management LP purchased a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth about $342,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).